Vaccine Preparation

Part of Vaccines

Formulating harvested biological material into a safe, stable, and effective vaccine product.

Why This Matters

Growing a culture, inactivating or attenuating the pathogen, and verifying sterility are necessary steps — but they produce a raw biological preparation, not a finished vaccine. Vaccine preparation is the process of formulating that raw material into a product with defined concentration, appropriate pH, added adjuvant or preservative, and correct volume — a product that can be reliably administered and expected to produce a protective immune response.

The difference between a raw culture and a formulated vaccine is the difference between flour and bread: the essential ingredient is the same, but the finished product requires processing, measurement, and quality control to be useful.

Vaccine preparation steps are also the last opportunity to catch and correct problems before a product enters the human body. This is where concentration is standardized, where sterility is verified, where adjuvant is mixed, and where final visual inspection can catch unexpected contamination or physical changes. No detail here is minor.

Overview of Preparation Steps

Standard sequence for a killed bacterial vaccine:

1. Grow culture to target density
2. Harvest (remove from growth medium if necessary)
3. Standardize concentration
4. Inactivate (heat or chemical)
5. Verify inactivation (culture test)
6. Add adjuvant (alum)
7. Filter for sterility (if injectable)
8. Check pH
9. Add preservative (if multi-dose)
10. Fill into final containers
11. Safety testing
12. Label and store

For live attenuated vaccine: Skip inactivation. Include potency test (verify viable organism count). No heating. Cold chain from this point onward.

Harvesting and Concentration

Most culture work produces the target organism suspended in large volumes of growth medium. Before formulation, the organism must often be separated from the medium and concentrated.

Centrifugation (if available): Spin at moderate speed (2,000-10,000 rpm) to sediment bacteria. Discard supernatant; resuspend pellet in sterile saline. Highly effective; requires centrifuge.

Improvised sedimentation: Allow culture to stand undisturbed in cold (4°C) for 12-24 hours. Heavy bacterial cells gradually sediment. Carefully aspirate and discard most of the supernatant; resuspend sediment in sterile saline. Less efficient than centrifugation but achievable without equipment.

Filtration concentration: Not practical for whole cells — standard filters remove bacteria from liquid rather than concentrating them. Works for viruses if ultrafiltration membranes are available.

After sedimentation and resuspension, the material is in a defined small volume of sterile saline — the working suspension.

Standardization of Concentration

Every batch of vaccine should contain a consistent amount of active material per dose. Without standardization, different batches produce different immune responses — unreliable protection.

Turbidity matching to McFarland standards: Prepare McFarland standards as described in Dilution and Dosing. Adjust bacterial suspension by diluting with sterile saline or concentrating by further sedimentation until turbidity matches target standard.

McFarland 3 corresponds to approximately 9 × 10⁸ bacteria/mL for E. coli — typical starting concentration for many bacterial vaccines.

Serial dilution to target: After turbidity standardization, prepare working dilution: Example: stock at 10⁹ /mL, target dose 5 × 10⁶ /dose in 0.5 mL injection:

• Needed concentration: 5 × 10⁶ / 0.5 mL = 10⁷ /mL
• Required dilution: 10⁹ ÷ 10⁷ = 100×
• Prepare 1:100 dilution: 1 mL stock + 99 mL sterile saline

For live vaccines: Count colonies from dilution plating to determine exact viable count. More accurate than turbidity (which counts dead and live cells equally). Set target CFU per dose based on historical effective dose data.

Formulating with Alum Adjuvant

Alum adsorption protocol:

1. Prepare alum: mix equal volumes of 1% aluminum sulfate solution and 1% sodium hydroxide solution. A white precipitate of aluminum hydroxide forms immediately.
2. Centrifuge or allow to settle; discard supernatant. Resuspend precipitate in sterile water — this is the alum adjuvant.
3. Mix vaccine suspension with alum at approximately 1:1 ratio (or adjust to 1-2 mg aluminum per mL final vaccine).
4. Allow to adsorb with gentle stirring at room temperature for 30-60 minutes.
5. Check: properly adsorbed material has reduced turbidity in the supernatant and increased turbidity in the adsorbed fraction (settled alum particles with antigen attached).

Why adsorption improves vaccines: Alum particles are taken up by dendritic cells at the injection site. Antigen attached to alum particles is delivered directly to these professional antigen-presenting cells, dramatically improving immune response.

Important: Do not adsorb live attenuated vaccines onto alum — the process may damage live organisms. Alum is for killed and toxoid vaccines.

Toxoid Preparation

For diseases caused by bacterial exotoxins, the vaccine antigen is an inactivated form of the toxin (toxoid).

Formaldehyde inactivation to produce toxoid:

1. Grow toxin-producing bacteria in optimal conditions. Toxin is secreted into the culture supernatant.
2. Remove bacteria by centrifugation or filtration.
3. Verify toxin presence (biological or biochemical assay — in practice, inoculate a test animal with culture supernatant and observe for specific toxin effects).
4. Add formaldehyde to 0.3-0.5% final concentration.
5. Incubate at 37°C for 3-4 weeks (tetanus toxoid) or 37°C for 1 week with subsequent 4°C incubation (diphtheria).
6. Verify inactivation: inject test animal with toxoid at dose that would have been lethal with native toxin. No illness = successful toxoid.
7. Verify retained immunogenicity: immunize animals with toxoid; challenge with native toxin; protected animals confirm efficacy.

Formaldehyde removal: Excess formaldehyde in a product causes local reactions. Remove by dialysis (if membrane available) or neutralize with sodium bisulfite. Without purification capability, formaldehyde-containing products should be used at minimum concentration consistent with inactivation.

pH Adjustment of Final Product

Physiological pH (7.0-7.4) is required for injectable products. Deviations cause local tissue damage and altered immune responses.

Check with available indicator:

• Litmus paper: pH 7 = purple-grey; < 7 = pink; > 7 = blue
• Red cabbage indicator: pH 7 = purple

Adjust:

• To increase pH: add dilute sodium bicarbonate (baking soda in water) drop by drop; mix; recheck
• To decrease pH: add dilute acetic acid (vinegar) drop by drop; mix; recheck

Final target: pH 7.0-7.4 for all injectable preparations.

Adding Preservative

For multi-dose vials, a preservative prevents bacterial contamination during repeated entry over days.

Phenol at 0.25%: Add 2.5 mL of 10% phenol solution per 100 mL of vaccine. Mix thoroughly. This is for killed vaccines only — phenol inactivates live organisms.

Thimerosal at 0.01%: Add 0.1 mL of 1% thimerosal solution per 100 mL vaccine. Check: thimerosal should not be used with vaccines containing aluminum adjuvant (interaction reduces effectiveness of both).

No preservative for single-dose: Single-dose preparations used within hours of opening do not need preservative. For use within a single vaccination session, no preservative is required.

Filling and Sealing

Fill into sterile vials: Under sterile conditions, transfer final prepared vaccine into sterile glass vials:

• Amber glass (protects from light degradation) if available; clear glass otherwise
• Fill level: leave 10% headspace to allow for gas exchange and prevent pressure buildup
• Insert sterile rubber stopper; crimp or seal with wax

Multi-dose vs. single-dose: Single-dose vials (0.5-1.0 mL): simpler management, no preservative needed, less waste per vial Multi-dose vials (10-20 doses/vial): economical, requires preservative, careful management

Final Release Testing

Before any batch enters use:

Sterility: Inoculate aliquot in broth; incubate 7 days; no growth.

Safety (general safety test): Inject 0.5 mL into each of 5 mice and 2 guinea pigs; observe 7 days; no illness or death.

Potency (for killed vaccines): Immunize animals; challenge with live virulent organism; protection must exceed defined minimum (historically 60-80% survival compared to unvaccinated controls).

Physical inspection: Clear or uniformly turbid (not clumped, no visible foreign particles, expected color).

Documentation: Batch record complete, all tests passed, expiry date assigned (based on stability data or conservative default).

Only batches passing all tests should be released. Document every test and result. The batch record is the paper trail that allows tracing of any problem that emerges after distribution.